Aging Skin | NYU Langone Health
Dermatologists and surgeons at NYU Langone offer injections, laser therapy, and cosmetic surgery to improve the appearance of aging skin.
AHCRN Registry: Characterizing Patient Populations in the Adult Hydrocephalus Clinical Research Network (AHCRN)
The AHCRN Registry has been developed to obtain data about hydrocephalus patientevents, treatments and outcomes from the network Clinical Centers, and to create a database to be used by AHCRN investigators. The ongoing maintenance of the Registry serves two main purposes: (1) it will help investigators understand the variability, progression, and current treatment practices for hydrocephalus in adults, with an ultimate goal of better guiding and assessing therapeutic intervention and providing recommendations on patient care and; (2) it will provide pilot and descriptive data necessary for hypothesis generation and study design (e.g., preliminary power analyses, recruitment projections) for studies under development by the AHCRN. This multi-institutional database will be useful for tracking trends in hydrocephalus over time. The Registry will be an invaluable resource to the AHCRN and will help stimulate new research protocols, identify potential need for future expansion of the network to incorporate additional patient populations, and provide a descriptive understanding of adults with hydrocephalus cared for within the network.
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
The primary objective is to compare the PFS of patients with early-stage cHL treated through aresponse-adapted design with either standard therapy or with an IO approach (brentuximab vedotin andnivolumab). Patients will be randomized to standard chemotherapy versus IO therapy following initialresponse assessment by PET/CT after two courses of ABVD. All will be stratified as favorable orunfavorable based on initial disease risk features, and those who are PET2 positive (defined as 5 PointScore, 5PS 4 or 5) will receive involved site radiotherapy (ISRT). Overall, RT exposure will be reducedcompared to prior COG HL trials but within the standard of care per National Comprehensive CancerNetwork (NCCN) pediatric lymphoma guidelines.The study expects to enroll 1875 patients over 5 years of accrual, for an estimated 1782 evaluable patients (PET2negative/rapid early responder [RER] n = 1514; PET2 positive/slow-early responder [SER] n = 268). Byexamining both shorter-term PFS and longer-term OS (12-year), and by prospectively collecting detaileddata on toxicity outcomes, this protocol will be practice changing for both pediatric and adult patientswith cHL and will ultimately define the role of an IO approach in the management of early-stage HL.This is a randomized trial comparing an IO approach with or without radiation therapy to a standard chemotherapy approach with or without radiation therapy in early stage cHL. All patients will be stratified by favorable vs. unfavorable features at studyenrollment. Patients are considered unfavorable if they have one or more of the following factors: (1) large mediastinal mass (> 10 cm by CT or 1/3 max chest diameter by CXR), (2) > 3 nodal sites, (3) B symptoms with ESR > 30, (4) ESR > 50 without B symptoms, and (5) age > 50 years. All patients will receive 2 cycles of ABVD chemotherapy. Subsequently, a rapidcentral review will be performed to determine early response assessment (PET2),which will be utilized to randomize patients to receive either conventionalchemotherapy or an IO approach with nivolumab and brentuximab vedotin. If a patientis deemed to not meet study eligibility staging criteria at the time of PET2 centralreview, the patient will be removed from protocol therapy. All SER patients (5PS 4, 5)will receive involved site radiation therapy (ISRT). Following randomization, thepatient may be assigned to one of the following treatment arms:• Arm A (Favorable RER, Standard Therapy): ABVD x 2• Arm B (Favorable RER, IO Therapy): Brentuximab vedotin + Nivolumab x 4 Arm C (Favorable SER, Standard Therapy): eBEACOPP x 2, ISRT• Arm D (Favorable SER, IO Therapy): Brentuximab vedotin + Nivolumab x 4, ISRT• Arm E (Unfavorable RER, Standard Therapy): AVD x 4• Arm F (Unfavorable RER, IO Therapy): Brentuximab vedotin + Nivolumab x 4• Arm G (Unfavorable SER, Standard Therapy): eBEACOPP x 2, ISRT• Arm H (Unfavorable SER, IO Therapy): Brentuximab vedotin + Nivolumab x 4, ISRT
AIDS-Related Lymphoma | NYU Langone Health
Doctors at Perlmutter Cancer Center provide expert care for people who have AIDS-related lymphoma, a group of cancers that begin in white blood cells.
Airway Abnormality Services for Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone offer advanced diagnostic tools and treatments for airway abnormalities in children.
Airway Center | NYU Langone Health
NYU Langone’s Airway Center provides evaluation and treatment for adults and children with upper airway problems.
Airway Center Doctors | NYU Langone Health
Find a doctor at the Airway Center at NYU Langone.
Airway Clearance for Nontuberculous Mycobacterial Infections | NYU Langone Health
NYU Langone doctors may recommend techniques to prevent mucus building up in the lungs from a nontuberculous mycobacterial infection.
Airway Clearance Techniques for Cystic Fibrosis in Children | NYU Langone Health
Experts at NYU Langone provide ongoing support and education on airway clearance techniques to treat cystic fibrosis in children.
Airway Monitoring for Cystic Fibrosis in Children | NYU Langone Health
Doctors at NYU Langone regularly monitor people with cystic fibrosis for signs of lung infections.